GlyphAgo
AssetAlso GlyphAgoTM
Modulates central neurotransmission to treat anxiety and sleep disturbance
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Not known
- 2
- Indications
- 0
- Trials
- 1
- Developer
Indications
2Generalized anxiety disorder
Phase 2, businesswire.com, 7 Oct 2026
Sleep disturbance
Phase 2, businesswire.com, 7 Oct 2026
In the full profile
- Owner and partners1
- Competitors1
Every asset’s record: target, stage, trials and the evidence behind it.